Director at Inhibitor Therapeutics (INTI) receives 50,000-share equity grant

Rhea-AI Filing Summary

Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.

Inhibitor Therapeutics, Inc. director Jerman Michael Allen received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. Following this award, he directly holds 180,411 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jerman Michael Allen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 180,411 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted shares granted: 50,000 shares Price per granted share: $0.0000 per share Shares held after grant: 180,411 shares +1 more

4 metrics

Restricted shares granted 50,000 shares Grant of restricted common stock as compensation

Price per granted share $0.0000 per share Reported transaction price for restricted stock grant

Shares held after grant 180,411 shares Total common stock directly owned after transaction

Transaction code A (Grant, award, or other acquisition) SEC Form 4 transaction classification

Key Terms

restricted common stock, 2025 Equity Incentive Plan, Form 4

3 terms

restricted common stock financial

"Represents restricted common stock issued to the Reporting Person as compensation"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

2025 Equity Incentive Plan financial

"as compensation pursuant to the Issuer's 2025 Equity Incentive Plan"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 12:35 PM Accepted by SEC EDGAR 06/24/2026 - 12:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jerman Michael Allen

(Last) (First) (Middle)

C/O INHIBITOR THERAPUTICS, INC.,

3014 WEST PALMIRA AVE SUITE 302

(Street)

TAMPA FLORIDA 33629

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		50,000(1)	A	$0	180,411	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

	/s/ Michael Jerman	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Inhibitor Therapeutics (INTI) director Jerman Michael Allen report on this Form 4?

He reported receiving 50,000 shares of restricted common stock as compensation. The award was made under Inhibitor Therapeutics’ 2025 Equity Incentive Plan and reflects equity-based compensation, not an open-market purchase or sale of existing shares.

How many Inhibitor Therapeutics (INTI) shares does Jerman Michael Allen hold after this grant?

After the grant, he directly holds 180,411 shares of common stock. This total includes the newly issued 50,000 restricted shares awarded as compensation under the company’s 2025 Equity Incentive Plan, according to the Form 4 disclosure.

Was cash paid for the 50,000 restricted shares reported by Inhibitor Therapeutics (INTI) director?

No cash was paid; the 50,000 restricted shares were issued at a reported price of $0.0000 per share. The Form 4 footnote explains they were granted as compensation under the 2025 Equity Incentive Plan, rather than purchased in the market.

What is the nature of the equity awarded to the Inhibitor Therapeutics (INTI) director?

The filing describes the award as restricted common stock issued as compensation. It was granted pursuant to Inhibitor Therapeutics’ 2025 Equity Incentive Plan, meaning the shares are subject to plan terms such as potential vesting or forfeiture conditions.

Does this Inhibitor Therapeutics (INTI) Form 4 show any share sales by the director?

The Form 4 does not show any sales; it reports only an acquisition coded as a grant. The transaction is categorized as a grant, award, or other acquisition of 50,000 restricted common shares, with no disposal transactions listed in the summary data.